Erythropoietin-induced reduction of hypoxia before and during fractionated irradiation contributes to improvement of radioresponse in human glioma xenografts.
Fiche publication
Date publication
mai 2004
Journal
International journal of radiation oncology, biology, physics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BARBERI-HEYOB Muriel, Pr CHASTAGNER Pascal, Pr MERLIN Jean-Louis, Dr PINEL Sophie
Tous les auteurs :
Pinel S, Barberi-Heyob M, Cohen-Jonathan E, Merlin JL, Delmas C, Plenat F, Chastagner P
Lien Pubmed
Résumé
Our study investigated the influence of recombinant human erythropoietin (rHuEPO) treatment, inducing raised hemoglobin levels in nonanemic mice, on intratumor oxygenation before and during fractionated irradiation. Furthermore, the consequences of rHuEPO administration on tumor response to fractionated radiotherapy (RT) were evaluated.
Mots clés
Animals, Cell Hypoxia, drug effects, Erythropoietin, pharmacology, Glioma, blood, Hemoglobins, drug effects, Humans, Mice, Mice, Nude, Oxygen, blood, Radiation Tolerance, drug effects, Recombinant Proteins, Transplantation, Heterologous
Référence
Int. J. Radiat. Oncol. Biol. Phys.. 2004 May;59(1):250-9